Print
Email
Print Edition StoriesThursday, May 29, 2008
Aveo Pharmaceuticals moves into Phase 2 with cancer drug
By Mass High Tech Staff
Officials at Aveo Pharmaceuticals Inc. report that the company has completed enrollment in a Phase 2 clinical trial of a drug to treat patients with metastatic renal cell carcinoma (mRCC).
The 200-patient, 16-week trial of the drug AV-951 will test the safety and effectiveness of once-daily, oral administration of the drug at more than 30 sites in Europe and India.
The drug AV-951 is an angiogenesis inhibitor, which slows the growth of blood vessels in tumors. Cambridge-based Aveo has also recently launched a Phase 1b trial of AV-951 in combination with temsirolimus in patients with mRCC.
In addition to its own clinical pipeline, Aveo has collaborations with Eli Lilly, Merck, OSI Pharmaceuticals and Schering-Plough.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
